b Henry
0
1
1
0
0
1
0.00
c Latham
b Foulkes
c Latham
b Foulkes
2
4
2
0
0
9
50.00
b Foulkes
2
6
4
0
0
10
33.33
Former India captain Sunil Gavaskar was left fuming after finding out that two Australian women’s cricketers were harassed in Indore on the sidelines of the Women’s World Cup 2025 edition. According to a statement released by Cricket Australia,…
The vivo X300 series is off to a strong start – the two new models got mostly positive results in last week’s poll. There is still the question of the global launch time frame and pricing hanging over them – the official launch is set…
Max Verstappen has issued a warning that his race pace for the Mexico City Grand Prix “is of course a big concern” as the Red Bull driver struggled on longer simulation runs despite topping Free Practice 2 on Friday.
The Dutchman enters this…
Sante publique France reports, as of October 20, 766 locally acquired chikungunya cases were reported in mainland France.
In addition, 29 local transmission of dengue fever have been reported this year.
91 outbreaks of indigenous vector-borne…
Samsung has announced that it’s secured a partnership with Paris’s famed Centre Pompidou museum that will bring no less than 25 of the gallery’s most famous and revered masterpieces to Samsung’s online digital Art Store, enabling Samsung…
Investor sentiment around UP Fintech Holding (NasdaqGS:TIGR) has picked up after UBS and Jefferies each began covering the company with optimistic outlooks. The analysts highlighted the company’s foothold in expanding Hong Kong and Singapore wealth markets as well as its financial momentum.
See our latest analysis for UP Fintech Holding.
The upbeat analyst attention and momentum in Hong Kong and Singapore have helped fuel a stellar run for UP Fintech, with a 53.9% year-to-date share price return and a striking 1-year total shareholder return of 66.1%. Both the recent buzz and the longer-term track record, up 173% over three years, suggest that optimism around the company’s growth story is gaining traction among investors.
If fresh analyst optimism has you rethinking your watchlist, this could be the perfect moment to broaden your investing horizons and discover fast growing stocks with high insider ownership
But with shares already rallying this year and analyst targets suggesting more upside, the question is whether UP Fintech’s impressive growth is still underappreciated or if markets have already accounted for those future gains.
With the latest narrative valuing UP Fintech at $14.12, the gap versus the last close at $10.28 has caught attention. This fair value, calculated using a specific set of forward-looking earnings and margin assumptions, shapes the current debate around where the market might move next.
Strong growth in revenue, assets, and profitability; expansion into high-potential markets; and ongoing tech innovation position UP Fintech for durable, scalable, and diversified earnings.
Read the complete narrative.
Record margins, bold revenue forecasts, and a future earnings multiple are at the heart of this narrative. Want to see what assumptions drive this eye-catching target? The reasoning behind these numbers will surprise you.
Result: Fair Value of $14.12 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, intensifying regulatory scrutiny and higher client acquisition costs in key markets could disrupt UP Fintech’s strong growth momentum and future profit forecasts.
Find out about the key risks to this UP Fintech Holding narrative.
If you think the numbers tell a different story or want to dig into the details yourself, you can craft your own take on UP Fintech in just a few minutes. Do it your way
A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding UP Fintech Holding.
eInfochips, an Arrow Electronics company, and NXP Semiconductors recently announced a multi-year collaboration focusing on software distribution and customer services for NXP’s S32 microcontrollers, aiming to accelerate the development of software-defined vehicles.
This partnership highlights Arrow’s ongoing efforts to expand its value-added engineering and software support capabilities within the automotive and embedded systems sectors.
We’ll examine how Arrow’s expanded role in automotive software solutions with NXP could impact its outlook for recurring, higher-margin services growth.
These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.
To be a shareholder in Arrow Electronics, you must believe that the company can successfully pivot toward higher-margin, recurring revenue streams as industrial, automotive, and connectivity trends drive demand for electronics content. While the recent eInfochips–NXP collaboration underscores Arrow’s ambitions in software and engineering services, it does not materially affect the immediate risk that automation and direct sourcing could weaken Arrow’s position in the traditional distribution business.
The most relevant recent announcement is Arrow’s appointment of an interim CEO in September 2025. This leadership change, closely following strategic partnerships, may impact Arrow’s agility in executing new service-focused initiatives as it aims for greater exposure to the software-defined automotive sector.
However, against this potential for a shift into higher-value offerings, investors should also recognize the risk if digital procurement trends accelerate and…
Read the full narrative on Arrow Electronics (it’s free!)
Arrow Electronics’ outlook suggests $35.2 billion in revenue and $734.1 million in earnings by 2028. This is based on an anticipated 7.3% annual revenue growth and a $266.9 million increase in earnings from the current $467.2 million.
Uncover how Arrow Electronics’ forecasts yield a $116.75 fair value, a 3% downside to its current price.
Two fair value estimates from the Simply Wall St Community both land at US$116.75, reflecting remarkably consistent expectations. Some see Arrow’s effort to expand recurring, engineering-related services as a turning point, but your experience could differ, explore alternative viewpoints to inform your decision.
Japan’s new HTV-X cargo spacecraft launched on its first-ever mission to the International Space Station on Saturday (Oct. 25).
Schrödinger (SDGR) has been featured as a key player in the recent industry spotlight on artificial intelligence innovation within biotechnology. The focus is on its work in AI-powered drug discovery and its support for clinical trials.
See our latest analysis for Schrödinger.
Schrödinger’s share price has climbed 18.2% over the last month, with momentum building amid a year-to-date rise of 10.4%. Over the past 12 months, total shareholder return hit 27.4%, highlighting renewed optimism after years of lagging performance.
Given the surge in biotech and AI-powered innovation, it could be the perfect moment to expand your research into other healthcare pioneers. See the full list for free with See the full list for free.
With shares trading nearly 20 percent below analyst price targets and impressive growth in both revenue and AI innovation, is Schrödinger offering a rare value opportunity, or is the market already accounting for its future ambitions?
Schrödinger’s most popular narrative puts its fair value at $27.30, notably higher than the last close at $22.52, suggesting the crowd still sees considerable upside. With impressive revenue growth and industry-leading technology, the long-term outlook appears optimistic, provided the bullish assumptions turn out to be true.
Expansion of large-scale strategic partnerships and collaborations (e.g., with Novartis, Lilly, and Otsuka), combined with consistent 100% retention among largest customers and robust renewal discussions, increase near and long-term earnings visibility and reduce churn risk, stabilizing future earnings and free cash flow.
Read the complete narrative.
What’s fueling such a premium price target? The most intriguing part is that this narrative leans on ambitious projections for recurring revenue, future software demand, and strong earnings visibility. Curious which numbers tip the scales? Dive into the full breakdown to see how these bold financial levers could drive exceptional returns.
Result: Fair Value of $27.30 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, a slowdown in new customer growth or pressure on software margins could quickly change this optimistic outlook for Schrödinger’s future earnings.
Find out about the key risks to this Schrödinger narrative.
Looking at the price-to-sales ratio, Schrödinger trades at about 7x, which is more than double the US Healthcare Services industry average of 3.2x and far above peer averages at 2.6x. The estimated fair ratio stands at just 3x. This stark gap suggests that, by this metric, the stock carries valuation risk if the market pulls back to more conservative benchmarks. Could momentum alone keep Schrödinger’s valuation on a premium path, or does this set up the potential for a reset?